Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

CMIP as a novel candidate gene for neurodevelopmental and neuropsychiatric disorders.

European journal of human genetics : EJHG·2026

Same author

Antimicrobial Prophylaxis in Solid Organ and Hematopoietic Stem Cell Transplantation: A Survey Among Member Centers of the European Reference Network TransplantChild.

Pediatric transplantation·2026

Same author

Climate change and pediatric neurology: A call to action.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society·2026

Same author

Closing the Gap to Interventions for Tuberous Sclerosis Complex-Associated Neuropsychiatric Disorders (TAND): Protocol for a Longitudinal Study of TAND Severity, Predictors, and Caregiver Well-Being (TANDem-2).

JMIR research protocols·2026

Same author

Bedside model-informed precision dosing of vancomycin in severely ill neonates and children in Belgium (the BENEFICIAL trial): a multicentre, randomised controlled trial.

The Lancet. Child & adolescent health·2026

Same author

Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study.

Orphanet journal of rare diseases·2026

Same journal

Not all acute peripheral facial palsy in children recovers completely: A telediagnostic follow-up study.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society·2026

Same journal

The prevalence of spinal muscular atrophy in Kazakhstan and the experience with the national nusinersen treatment program.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society·2026

Same journal

Motor-free visual perception and visuomotor integration in pediatric arterial ischemic stroke.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society·2026

Same journal

Familial, recurrent or genetic acute necrotizing encephalopathy of childhood: a systematic review and a case report. Focus on atypical events and on the role on immunizations.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society·2026

Same journal

Cenobamate in pediatric epilepsy: Moving beyond anecdotal experience.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society·2026

Same journal

Re: Diodato et al. "Distal arthrogryposis with impaired proprioception and touch: description of 9 additional cases harbouring novel PIEZO2 variants and literature review" (European Journal of Paediatric Neurology 61, 2026, 24-35).

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jul 25, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Metachromatic leukodystrophy: To screen or not to screen?

An I Jonckheere¹, Sandra D K Kingma², François Eyskens²

¹Department of Child Neurology, Antwerp University Hospital, University of Antwerp, Edegem, Belgium; Centre for Metabolic Diseases, University Hospital Antwerp, University of Antwerp, Edegem, Belgium.

European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society

|June 24, 2023

Summary

This summary is machine-generated.

Metachromatic leukodystrophy (MLD) treatment is evolving. Hematopoietic stem cell transplantation outcomes vary, prompting development of new therapies and newborn screening for MLD.

Keywords:

Metachromatic leukodystrophy Newborn screening Treatment

More Related Videos

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

An Electrochemiluminescence-Based Assay for MeCP2 Protein Variants

An Electrochemiluminescence-Based Assay for MeCP2 Protein Variants

Published on: May 22, 2020

Related Experiment Videos

Last Updated: Jul 25, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

An Electrochemiluminescence-Based Assay for MeCP2 Protein Variants

An Electrochemiluminescence-Based Assay for MeCP2 Protein Variants

Published on: May 22, 2020

Area of Science:

Neuroscience
Genetics
Biochemistry

Background:

Metachromatic leukodystrophy (MLD) is a neurodegenerative lysosomal storage disorder.
It results from pathogenic variants in the arylsulfatase A gene.
MLD presents with variable onset, including infantile, juvenile, and adult forms.

Purpose of the Study:

To review the outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for MLD.
To discuss emerging curative treatment options for MLD.
To explore the potential of newborn screening for MLD.

Main Methods:

This is a narrative review.
Literature search on MLD treatments, including allo-HSCT and novel therapies.
Analysis of treatment outcomes based on MLD disease forms and onset age.

Main Results:

Allo-HSCT outcomes for MLD are variable with high morbidity.
Newer treatment strategies are being developed, some with curative potential.
Newborn screening for MLD is increasingly considered valuable.

Conclusions:

The therapeutic landscape for MLD is shifting towards innovative treatments.
Newborn screening for MLD is gaining importance due to evolving treatment options.
Early detection through newborn screening may improve MLD management.